BioCentury | Nov 14, 2020
Regulation

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

...netarsudil/latanoprost (PG324) Phesgo Xofluza baloxavir marboxil (RG6152, S-033188) Elzonris (tagraxofusp-erzs, SL-401) Biosimilar bevacizumab Gamifant...
BioCentury | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

...OTCQX:RHHBY). Targets: HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos, Associate Editor Zirabev, biosimilar bevacizumab...
BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...been determined. Coherus takes territorial rights to Innovent’s Avastin biosimilar Innovent Biologics Inc. (HKSE:1801) granted Coherus BioSciences...
...subcutaneous semaglutide (Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent Biologics Inc. Coherus BioSciences...
BioCentury | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

...as its first chief commercial officer. Hassard was SVP of marketing and market access at Coherus BioSciences...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...pegfilgrastim launched in the U.S. in July 2018, it has been joined by Udenyca from Coherus Biosciences...
...CenTNF (Former), Avakine (Former), infliximab (Generic), Remicade (Other) Novartis AG Amgen Inc. Samsung Bioepis Co. Ltd. Mylan N.V. Sandoz IQVia Holdings Inc. Coherus BioSciences...
BioCentury | Nov 5, 2019
Company News

Sandoz to launch third Neulasta biosimilar

...sales in 3Q19, with a 31% decline in the U.S. FDA approved Udenyca pegfilgrastim-cbqv from Coherus Biosciences...
...$120 million. Mylan did not break out sales of its biosimilar. Steve Usdin, Washington Editor Sandoz Ltd. Amgen Inc. Coherus BioSciences...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

...in the paper laying out the CSL proposal, he said. Forum members include Boehringer Ingelheim, Coherus BioSciences...
...LLC, Washington, DC BioApprovals, Acton, Mass. Biosimilars Forum, Washington, DC Boehringer Ingelheim GmbH, Ingelheim, Germany Coherus Biosciences...
...Israel U.S. Food and Drug Administration (FDA), Silver Spring, Md. Steve Usdin, Washington Editor Amgen Inc. Boehringer Ingelheim GmbH Coherus BioSciences...
BioCentury | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

...CT-P26, CT-P06) Inflectra, Remsima, biosimilar infliximab-dyyb (CT-P13) Kanjinti, biosimilar trastuzumab (ABP 980) Mvasi (Brand), ABP 215 (Compound #), biosimilar bevacizumab...
BioCentury | Jun 28, 2019
Company News

June 28 Company Quick Takes: FDA approves Pfizer's biosimilar of Avastin; plus Aimmune, PeptiDream, Novartis and Just/Teva

...S. Eaton, Staff Writer AR101, arc001, peanut allergy oral immunotherapy (oit) Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) Zirabev, biosimilar bevacizumab...
BioCentury | Feb 5, 2019
Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

...of business development at Denali Therapeutics Inc. (NASDAQ:DNLI), and Robbins was VP of IP at Coherus BioSciences...
Items per page:
1 - 10 of 155